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Background: Patients with incurable thoracic cancer often complain of a reduced ability to
exercise, but the cause of this has been little studied. Thus, we have explored how various
physiological and psychological factors relate to exercise performance in this group.
Methods: Inspiratory muscle strength, peripheral muscle power, lung function and mastery
over breathlessness were assessed using sniff nasal inspiratory pressure, leg extensor power,
simple spirometry and the mastery domain of the Chronic Respiratory Disease Questionnaire
respectively. Exercise performance was assessed using the Incremental Shuttle Walking Test
(ISWT) during which patients wore a K4 b2 system permitting measurement of resting and
breakpoint heart rate, minute ventilation (VE) and oxygen uptake (VO2). Relationships
between ISWT distance and the four factors were determined using correlation and b regression
coefficients.
Results: Forty-one patients (21 male, mean (SD) age 64 (8) years) walked a median [IQR] of 320
[250e430] metres and reached a mean (SD) of 76 (10), 77 (25), and 48 (14) of their percent
predicted maximum heart rate, VO2, and VE respectively. Exercise performance was signifi-
cantly associated only with inspiratory muscle strength (r Z 0.42, P < 0.01) and peripheral
muscle power (rZ 0.39, P Z 0.01). These factors were also significant determinants of exer-
cise performance (b coefficients [95%CI] 1.77 [0.53, 3.01] and 1.22 [0.31, 2.14] respectively).
Conclusion: Of the factors examined, only inspiratory and peripheral muscle performance
were significantly related to and predictive of exercise performance. Rehabilitation interven-
tions which include inspiratory and peripheral muscle training are worth exploring further in
this group of patients with thoracic cancer.
ª 2011 Elsevier Ltd. All rights reserved.use Specialist Palliative Cancer Care Unit, Nottingham University Hospitals NHS Trust, City Hospital
l.: þ44 (0) 115 962 7778; fax: þ44 (0) 115 962 7779.
ottingham.ac.uk (A. Wilcock).
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Patients with incurable thoracic cancer often complain of
a reduced ability to exercise which can impede levels of
physical activity, independence and quality of life.1,2 It is
generally assumed that this mainly results from the cancer
interfering with the normal ventilatory function of the
lungs, chest wall or diaphragm, particularly as exertional
breathlessness is also common.3e5 However, there has been
little formal study in this group and this assumption may or
may not be correct. For example, in patients with chronic
obstructive pulmonary disease, who also have impaired
ventilation and experience breathlessness, quadriceps
muscle strength is the strongest predictor of exercise
performance.6,7
Our group is interested in developing rehabilitation
interventions for patients with incurable thoracic cancer,
to be offered soon after diagnosis, alongside or following
initial anticancer therapy, with the aim of maintaining
reasonable levels of physical activity and independence for
as long as possible. Identifying appropriate interventions
will be informed by a greater understanding of the factors
which influence exercise performance. Thus, this study
examines how inspiratory and peripheral muscle function,
simple spirometry and feeling of mastery relate to exercise
performance in this group of patients.
Methods
Patients with incurable thoracic cancer and an Eastern
Cooperative Oncology Group (ECOG) performance status of
0e2 reporting a subjective reduction in ability to undertake
their usual activities since their diagnosis of cancer were
recruited from outpatient clinics at Nottingham University
Hospitals NHS Trust. Patients were excluded if a palliative
intervention was appropriate to improve their exercise
capacity, e.g. drainage of a pleural effusion, they had
ischaemic heart disease, pain affecting their ability to
walk, or if they had received chemotherapy or radiotherapy
within the last 4 weeks. Those with chronic obstructive
pulmonary disease (COPD) were included if this was clini-
cally stable and not considered to be responsible for their
recent decrease in exercise capacity. The dose of any drugs
that may have affected the ability to exercise had to have
been stable for at least one week. All provided written
informed consent and the study was approved by the
Hospital Ethics Committee (EC99/45).
Measurements
Inspiratory muscle strength
Assessed by measuring sniff nasal inspiratory pressure
(SNIP) with the patient standing, using a modified PK
Morgan Pmax monitor (PK Morgan, Rainham, Kent, UK).
With a closed mouth, the patient takes 10 short, sharp
sniffs using maximal effort with one nostril occluded by
a nasal pillow attached to a syringe barrel which is con-
nected via a line to the pressure transducer. The highest
value obtained was expressed as a percentage of the pre-
dicted normal value, adjusted for age and sex, and used for
analysis.8e10Peripheral muscle power
Assessed using a purpose built leg extensor power (LEP) rig,
consisting of a seat and a footplate connected through
a lever and a chain to a flywheel.11 The patient, in a seated
position with folded arms, applies maximum force with
their dominant leg to push the footplate away from 60
knee flexion into full extension and accelerate the flywheel
from rest. The final angular velocity of the flywheel is
measured by an opto-switch and used to calculate average
leg extensor power, expressed as Watts/kilogram body
weight (W/kg). After 2e3 practice attempts for familiar-
isation purposes, 10 pushes were undertaken with stand-
ardised verbal encouragement and the maximum value
used for analysis. In a large sample of healthy older (50
years) men and women, mean (SD) values of 3.1 (1.1) and
2.0 (0.8) W/kg respectively have been recorded, with
power declining with age.12
Simple spirometry
Forced expiratory volume in 1 s (FEV1) and forced vital
capacity (FVC) were measured as the best of three
measurements within 100 ml using a dry wedge spirometer
(Vitalograph Type R Spirometer, Buckingham UK) with the
patient seated. Results were expressed as absolute (Litres,
L) and percent predicted values, adjusted for age and sex,
and the FEV1:FVC ratio calculated.
Mastery
Assessed using the Chronic Respiratory Disease Question-
naire (CRDQ). This consists of 20 items covering four
dimensions: dyspnoea, fatigue, emotion and mastery. Four
questions make up the mastery dimension, with answers
selected from a 7-point categorical scale. Each answer is
scored numerically and summated to give a total score for
the dimension. Scores range from 4 to 28, with a higher
score indicating greater level of mastery.13
Exercise performance and ventilation, oxygen uptake,
heart rate, blood gases and symptoms limiting exercise
Exercise performance was assessed using the Incremental
Shuttle Walking Test (ISWT; Department of Respiratory
Medicine, Glenfield Hospital, Leicester, UK).14 The patient
walks around a 10 m ‘shuttle’ course defined by two marker
cones at a speed dictated by audio signals from a calibrated
tape cassette. The test speed increases every minute until
the patient reaches their breakpoint, defined as the point
at which the patient is unable to continue or cannot
maintain the required walking speed. Testing was also
stopped if the patient exceeded their maximum predicted
heart rate. The total distance walked to the last fully
completed 10 m shuttle was recorded.
Ventilation, oxygen uptake and heart rate were
measured using a COSMED K4 b2 (COSMED, Rome, Italy).15
This lightweight (800 g, including battery) portable tele-
metric gas analysis system is worn by the patient in
a harness. Respiratory flow and volume are measured by
the patient breathing through a tightly fitting facemask
containing a 28 mm diameter bi-directional digital turbine
flowmeter (resistance, flow range, ventilation range,
volume resolution, accuracy of <0.7 cm H2O L s
1 at
12 L s1, 020 L s1, 0e300 L min1, 4 mL, 2% respec-
tively). Oxygen uptake is assessed breath by breath using
296 R. England et al.a thermostated oxygen analyser (range, accuracy, response
time 7e24%, 0.02%, <160 msec respectively). Before use,
the flowmeter and oxygen analyser were calibrated using
a 3 L syringe and cylinder air respectively in accordance
with the manufacturer’s instructions.
Heart rate was measured using a wireless double elec-
trode heart rate monitor on a chest belt (HR Polar trans-
mitter, Polar Electro UK Ltd, Warwick, UK) fastened around
the lower chest at the level of the fifth intercostal space.
During the study, intermittent problems with the heart rate
monitor telemetry were encountered; these persisted even
with replacement belts, and were probably due to elec-
tromagnetic interference. Subsequently, as a back up,
patients also wore a wrist pulse oximeter (Pulsox 3i, Min-
olta, Osaka, Japan) to measure heart rate if necessary via
a finger probe sited on the index finger.
The K4 b2 and its software (COSMED data management
software v8.1) provide continuous data which, via telem-
etry, is accessible on a remote computer in real time.
Ventilation (VE; L min1), oxygen uptake (VO2;
mL min1 kg1) and heart rate (beats min1) at rest and at
breakpoint of the ISWT, expressed as absolute and percent
of maximum predicted values, were used for analysis.
Blood pH, PaO2 and PaCO2 were analysed using
a portable blood gas machine (Osmetch Opti CCA, GMI,
Minnesota, USA). Arterialised capillary blood was collected
from a finger tip using a lancet and capillary tube at rest
and at breakpoint. If necessary, this was facilitated by prior
immersion of the patient’s hand in warm water.
At breakpoint, patients were asked to report the main
symptom(s) limiting exercise as ‘breathlessness alone’, ‘leg
fatigue alone’, ‘breathlessness and leg fatigue equally’ or
‘other’, and to rate the severity of their breathlessness or
leg fatigue by pointing to a modified Borg scale,16 repro-
duced in large print on a board held by one of the
researchers.Excluded, n=38
♦declined information sheet (n=36)
♦deteriorated prior to consent (n=2)
Recruited, n=41
Analysed:
♦paired blood gases (n=33)
♦all other assessments (n=41)
Approached, n=79
Figure 1 Study flow chart.Protocol
Patients were given written instructions to avoid caffein-
ated drinks within 1 h, large meals within 2 h, and excess
alcohol the night before the test. They were asked to take
their usual medication as prescribed and advised to wear
comfortable walking shoes. The study was conducted
uninterrupted in a large room.
Drug use and smoking history were noted and a 12-lead
electrocardiogram was performed to exclude unexpected
cardiac pathology. Height and weight were recorded.
Patients underwent tests of simple spirometry, sniff nasal
inspiratory pressure (SNIP), leg extensor power and
completed the mastery questionnaire. A 5 min rest period
was allowed between each assessment for recovery. The K4
b2 mask and harness were then fitted and the patient sat
resting for 5 min and listened to pre-recorded instructions
on how to complete the ISWT from the supplied tape
cassette. An initial ISWT was undertaken for familiarisation
purposes. After completing the walk, patients were seated
until breathlessness scores and heart rate had returned to
baseline values. The K4 b2 equipment was removed and the
patient rested for 1 h, during which they were permitted
one (non-caffeinated) drink. A second ISWT was thenundertaken, with arterialised capillary blood gases ob-
tained immediately before and after the walk. On
completing the walk, patients sat until breathlessness
scores and heart rate had returned to baseline values.
Statistical analysis
Data were described by mean (standard deviation, SD) and
median [interquartile range, IQR] as appropriate. Pearson’s
correlations were used to determine correlations between
exercise performance and inspiratory muscle strength,
peripheral muscle power, FEV1 and FVC. Spearman’s rank
was used to determine correlations between exercise
performance and mastery domain score. Simple linear
regression was used to further explore the relationship
between these variables and exercise capacity, with
b regression coefficients and their 95% confidence intervals
reported. All calculations were performed using the
Statistical Package for Social Sciences (SPSS) v17.0 and P
values of <0.05 were regarded as statistically significant.
Results
Participants
Of 79 eligible patients approached, 41 were recruited and
completed the study (Fig. 1). Measurements were
completed in full except for blood gases, with paired
resting and breakpoint samples unavailable in eight
patients. Generally this was due to difficulty in collecting
a timely and sufficient sample of blood into the capillary
tube despite use of warm water, ‘milking’ the finger and
repeated stabs with the lancet; in two instances, the
portable blood gas machine failed despite an adequate
sample, and two patients declined to have the sample
undertaken (Fig. 1).
Participants (21 male) had a mean (SD) age of 64 (8)
years and a median (range) ECOG performance status of 1
(0e2); 26 had non-small cell lung cancer (NSCLC), 11
mesothelioma and four small cell lung cancer. Mean (SD)
body mass index was 25.4 (3.8) kg/m2 and percentage
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and one participants respectively were taking regular or ‘as
required’ inhaled bronchodilators, although only five had
a documented diagnosis of COPD (Table 1). To date 33
patients have died with a median [IQR] survival of 47
[2977] weeks.Table 1 Patient details. Mean (SD) or number of group
unless specified otherwise.
Age, years 64 (8)
Gender, male:female 21: 20
Diagnosis
Non-small cell 26
Mesothelioma 11
Small cell 4
ECOG performance status
0/1/2 16/21/4
Disease extent
Local/advanced 21/20
Metastases
Lymph nodes/lung/bone/
liver/adrenal
12/6/4/2/1
Previous treatments
Palliative chemotherapy 26
Palliative radiotherapy 10
Radical radiotherapy 1
Cigarette smoking status
Ex smoker 27
Current 7
Never 7
Relevant comorbidities
COPD 5
Osteoarthritis 3
Hypertension 4
Diabetes 4
Recent pulmonary embolism 1
Current medication
Inhaled corticosteroid 5
Inhaled bronchodilator 2
Oral corticosteroid 2
Diuretic 2
Low molecular weight heparin 1
Anthropometry
Height, cm 169 (10)
Weight, kg 73 (14)
Body mass index, kg m2 25.4 (3.8)
Inspiratory muscle strength
Actual, cmH2O 58 (32)
% Predicted 63 (32)
Leg extensor power
Watts 90 (43)
Watts/kg 1.23 (0.52)
Spirometry
FEV1, L 1.62 (0.59)
FEV1 % predicted 60 (19)
FVC, L 2.15 (0.73)
FVC % predicted 64 (18)
FEV1:FVC% 0.75 (0.11)
<70% 25
70% 16
Mastery score, median [IQR] 25 [2127]Exercise performance
Patients walked a median [IQR] distance of 320 [250e430]
metres over a mean (SD) test duration of 358 (95) seconds
and final test walking speed of 5.11 (0.99) km h1. The
group reached a mean (SD) of 76 (10), 77 (25) and 48 (14) of
their percent predicted maximal heart rate, peak oxygen
uptake, and ventilation respectively (Table 2). Reasons
given for stopping were shortness of breath alone (28),
shortness of breath and leg fatigue equally (9) and leg
fatigue alone (3). One patient reported general fatigue as
their limiting symptom (Table 2). For the group as a whole,
breathlessness was rated higher than leg fatigue at break-
point with median values of 3 ‘moderate’ and 0 ‘none at all’
respectively.
Factors associated with exercise performance
Exercise performance was moderately and significantly
correlated with inspiratory muscle strength (r Z 0.42,
P Z 0.01) and peripheral muscle power (r Z 0.39,
P Z 0.01), but not spirometric values or mastery domain
score (Table 3). Simple linear regression of the factors
revealed only inspiratory muscle strength and peripheral
muscle power to be significant determinants of exercise
performance, with regression coefficients [95% CI] of 1.77
[0.53, 3.01] and 1.22 [0.31, 2.14] respectively (Table 3).
Discussion
This study is the first to explore how a number of physio-
logical and psychological factors influence exercise
performance in a progressive walking test in patients withTable 2 Mean (SD) physiological measurements.
At rest Breakpoint
Heart rate
Beats per minute 81 (15) 118 (15)
% Predicted maximum 52 (10) 76 (10)
Oxygen uptake
VO2, mL kg
1 min1 5.0 (2.4) 18.3 (6.2)
% Predicted maximum 21 (10) 77 (25)
Ventilation
L min1 14.4 (6.7) 37.5 (14.7)
% Predicted maximum 19 (8) 48 (14)
Reason for stopping
Breathlessness e 28
Breathlessness and
leg fatigue
e 9
Leg fatigue e 3
General fatigue e 1
Borg Scores, median [IQR]
Breathlessness 0 [00] 3 [24]
Leg fatigue 0 [00] 0 [03]
Blood gases
O2, kPa 9.3 (3.1) 9.8 (2.9)
O2, mmHg 69.6 (23.5) 73.3 (21.7)
CO2, kPa 5.2 (1.0) 4.9 (0.9)
CO2, mmHg 38.9 (7.2) 37.2 (6.6)
Table 3 Correlations between exercise performance and
baseline measurements.
Baseline measurement r b [95% CI] P
Inspiratory muscle
strength
0.42 1.77 [0.53, 3.01] 0.01
Peripheral muscle
power
0.39 1.22 [0.31, 2.14] 0.01
% Predicted FEV1 0.22 1.50 [0.68, 3.66] 0.17
% Predicted FVC 0.21 1.54 [0.82, 3.90] 0.20
Mastery domain
score
0.21 5.74 [3.40,14.87] 0.18
298 R. England et al.incurable thoracic cancer. We found that in a group with
a reasonable performance status and limited weight loss,
who mainly experience breathlessness as the symptom
limiting exercise, inspiratory muscle strength and periph-
eral muscle power helped predict exercise performance,
but not spirometric values or mastery. Further, breakpoint
values did not suggest that cardiac factors or hypoxaemia
were factors limiting exercise.
There are no directly comparable studies to ours.
Patients with other cancers have been compared tomatched
healthy volunteers during treadmill exercise.5,17 Exercise
performance was found to relate to inspiratory muscle
strength (rZ 0.40, P< 0.01) in patients with various cancers
presenting with unexplained breathlessness on exertion,5
and to peripheral muscle mass (r Z 0.42, P < 0.01) in
patients with pancreatic cancer.17 With less peripheral
muscle mass, the anaerobic threshold is reached at lower
workloads, resulting in a reduced exercise capacity.
We found breathlessness, rather than leg muscle
fatigue, to be the most common symptom limiting exercise.
This could suggest that inspiratory muscle weakness plays
a particular role in the generation of breathlessness in this
setting, i.e. neuro-mechanical uncoupling occurs as the
ventilatory pump becomes unable to match the increased
demands of exercise.18 On the other hand, peripheral
muscle could also contribute to breathlessness as it may
directly influence the ventilatory response to exercise via
the ergoreflex.19 This reflex is enhanced in the presence of
a reduced peripheral muscle mass (more work per unit
volume) or muscle dysfunction (more rapid accumulation of
waste metabolic products) and is considered to contribute
to the increased ventilatory response to exercise and
breathlessness in patients with heart failure.19 The role of
leg muscle fatigue may become more relevant with greater
degrees of muscle wasting. In a hospice setting, of patients
with various cancers with breathlessness on exertion, about
half reported leg muscle fatigue as the symptom limiting
exercise.20
There are a number of limitations to the study. The
group was heterogeneous, including both lung cancer and
mesothelioma, whose disease may impact differently on
lung, chest wall or diaphragm function. However, compar-
ison of both groups revealed no significant difference in any
of the factors studied at baseline (data not shown).
Further, exclusion of mesothelioma made little difference
to the associations between exercise performance and
inspiratory muscle strength (r Z 0.42, P Z 0.01) orperipheral muscle power (rZ 0.44, PZ 0.01). Recruitment
took some time because of various factors, including diffi-
culty in finding suitable patients. Many were ineligible
because of concurrent ischemic heart disease and other
comorbidities and this may limit the generalisability of our
findings. Our data for numbers excluded was incomplete;
however, the presence of multiple comorbidities was the
main reason why three-quarters of patients with advanced
NSCLC screened for a study exploring the safety and
feasibility of cardiopulmonary exercise testing were ineli-
gible.21 We did not examine other factors which may help
predict exercise performance, e.g. left ventricular func-
tion.22 The use of the K4 b2 allowed us to measure various
parameters during a walking test, a more familiar form of
exercise than treadmill or cycle testing, and to demon-
strate that comparable mean absolute and percent pre-
dicted values of VO2 at breakpoint are reached as in
patients with advanced NSCLC undergoing cycle ergometry
(17 mL kg1 min1 and 67% respectively).21 However, the K4
b2 is expensive (about £18k/$30k), needs off-site servicing
every 6 months, and requires training in its set up, cali-
bration and use. Further, some patients found the tight
fitting face mask uncomfortable. We used SNIP as a simple,
non-invasive assessment of inspiratory muscle strength.
However, it can underestimate strength because it is
dependent on volition, and also because of reduced trans-
mission of pressure from the oesophagus to the nose in
patients with obstructive airways disease.23 Capillary blood
gases tend to underestimate oxygen values,24 but were
used mainly to exclude falling levels at breakpoint. Prac-
tical difficulties in obtaining a sufficient sample led to an
incomplete data set, but this did not suggest a decrease
with exertion.
We purposely recruited patients with a reasonable
performance status as we consider that it is this group for
whom proactive rehabilitation therapies have the greatest
potential to improve, maintain or slow the decline in
exercise ability. It is also pragmatic, as less fit patients are
less likely to be capable or willing to undertake and
complete a therapeutic exercise programme. Nonetheless,
new approaches are likely to be required as currently only
about half of patients with or cured of cancer offered an
exercise programme will complete one.25,26 One approach
our group is exploring is neuromuscular stimulation of the
quadriceps muscles. Having completed a pilot study,27 we
are now examining its use alongside palliative
chemotherapy.
In conclusion, of the factors examined, only inspiratory
and peripheral muscle performance were significantly
related to and predictive of exercise performance in
patients with thoracic cancer and a reasonable perfor-
mance status. This suggests that rehabilitation interven-
tions which include inspiratory and peripheral muscle
training are worth exploring further in this group.Acknowledgements
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